Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
Gabriel Rinnerthaler(Medical University of Graz), Richard Greil(Paracelsus Medical University), Lukas Weiß(Paracelsus Medical University), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Ursula Denison(Karl Landsteiner Society), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Knauer(Breast Center), Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Lidija Sölkner(Austrian Breast & Colorectal Cancer Study Group), Simon Peter Gampenrieder(University of Salzburg), Christine Brunner(Innsbruck Medical University), Clemens A. Schmitt(Kepler Universitätsklinikum), Rupert Bartsch(Universitätszahnklinik Wien), Nadja Zaborsky(University of Salzburg), Karl Sotlar(University of Tübingen), Daniel Egle(Innsbruck Medical University), Verena Wieser(Innsbruck Medical University), Maximilian Marhold(Medical University of Vienna), Carmen Albertini(Innsbruck Medical University), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Bruno Schneeweiß(University of Vienna), Magdalena Ritter(Innsbruck Medical University), Florian Posch(Medical University of Graz), Manuela Gili(Austrian Breast & Colorectal Cancer Study Group), Renate Pusch(Kepler Universitätsklinikum)
Cited by 10
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k